Cel­gene dou­bles down on Drag­on­fly­'s nat­ur­al killer tech, ex­pand­ing in­to sol­id tu­mors with an in­jec­tion of 'am­pli­fi­ca­tion cap­i­tal'

You can fund a biotech by sell­ing eq­ui­ty or rais­ing non-di­lu­tive cash, but Bill Haney says am­pli­fi­ca­tion cap­i­tal is the best mon­ey out there.

Par­tic­u­lar­ly when it comes from the likes of Cel­gene.

The CEO at Drag­on­fly Ther­a­peu­tics tells me this morn­ing that Cel­gene $CELG has agreed to dou­ble down on its ini­tial pre­clin­i­cal, hema­tol­ogy-on­ly ap­proach to treat­ing can­cer, adding a range of 4 new sol­id-tu­mor pro­grams to the menu as the start­up plots a di­rect path to the clin­ic. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER